NEW YORK (Reuters Health) – A low-dose regimen of peginterferon, without ribavirin, produces a sustained virologic response in up to 40% of patients with chronic hepatitis C and end-stage renal disease on dialysis, results of an international study indicate.
Hepatitis C virus infection is associated...